SCHEMBL1394293

SCHEMBL1394293

Cc1cc(Cl)nn2cc(-c3ccc(F)cc3)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.50
RAB9A P51151 9/20 0.50
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 5/20 0.49
NFKB1 P19838 3/20 0.49
NFKB2 Q00653 3/20 0.49
RELA Q04206 3/20 0.49
TP53 P04637 3/20 0.49
HSD17B10 Q99714 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.45
LMNA P02545 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
RECQL P46063 1/20 0.45
F2RL3 Q96RI0 1/20 0.43
MAPT P10636 4/20 0.40
HPGD P15428 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925086 0.83 APP (0.47) NPC1RAB9AKDM4EALDH1A1NFKB1
SCHEMBL3114238 0.78 NPC1 (0.51) NPC1RAB9AKDM4EALDH1A1NFKB1
SCHEMBL22077108 0.74 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1NFKB1
SCHEMBL1394164 0.74 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1NFKB1
SCHEMBL477053 0.73 ALDH1A1 (0.41) NPC1RAB9AKDM4EALDH1A1NFKB1
SCHEMBL1395044 0.73 DRD2 (0.49) NPC1RAB9AKDM4EALDH1A1NFKB1
SCHEMBL4920006 0.72 APP (0.49)
Bromide SCHEMBL25241165 0.72 ALDH1A1 (0.40) NPC1RAB9AKDM4EALDH1A1NFKB1
Hydrochloric Acid SCHEMBL21979887 0.72 ALDH1A1 (0.40) NPC1RAB9AKDM4EALDH1A1NFKB1
SCHEMBL16598490 0.71 KDM4E (0.44) NPC1RAB9AKDM4EALDH1A1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370446-B1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-11-25 EP disclosed
EP-2370446-B1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-11-25 EP disclosed
US-8546395-B2 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US disclosed
US-8546395-B2 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US disclosed
US-8546395-B2 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US disclosed
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 US disclosed
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 US disclosed
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 US disclosed
WO-2010063929-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CBR3, CBR1, CNR1 NPC1 1900/4885RAB9A 1770/4885KDM4E 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.